A majority of patients with angina related to coronary artery disease respond to medical management, percutaneous coronary intervention (PCI), or coronary artery bypass grafting (CABG). There is, however, a growing number of patients who have medically refractory angina caused by diffuse coronary artery disease who are not eligible for PCI or CABG owing to diffuse, distal disease.1 Treatment options are limited for this subset of patients.
KeywordsPercutaneous Coronary Intervention Coronary Artery Bypass Grafting Sham Group Placebo Effect Chronic Total Occlusion
Unable to display preview. Download preview PDF.
- 4.Byerly, H. 1976. Explaining and exploiting placebo effects. Perspect. Biol. Med. 10:423–435.Google Scholar
- 11.Leon, M. B., Baim, D. S., Moses, J. W., et al. 2000. A randomized blinded clinical trial comparing percutaneous laser myocardial revascularization (using Biosense LV mapping) in patients with refractory coronary ischemia. Circulation. 102:II–565.Google Scholar
- 18.Aaberge, L., Rootwelt, K., Blomhoff, S., et al. 2002. Continued symptomatic improvement three to five years after transmyocardial revascularization with CO2 laser: a late clinical follow-up of the Norwegian randomized trial with transmyocardial revascularization. J. Am. Coll. Cardiol. 39:1588–1593.CrossRefGoogle Scholar
- 20.Gibbons, R., Abrams, J., Chatterjee, K., et al. 2003. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina (summary article): a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Chronic Stable Angina). Circulation. 107:149–158.CrossRefGoogle Scholar